Fig. 1. β-APP overexpression or exposure to inflammatory mediators induces sIBM-like pathology in cultured rat myocytes that is abrogated by arimoclomol.

Slides:



Advertisements
Similar presentations
Fig. 1. TP is highly expressed in myeloma.
Advertisements

Fig. 7. Downstream effects of α-synuclein on mitochondria.
Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.
Fig. 1. FMRP deficiency leads to increased NSC activation in the adult dentate gyrus. FMRP deficiency leads to increased NSC activation in the adult dentate.
Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.
Transfer of miR-223 during neutrophil-epithelial cell interactions
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.
Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.
Fig. 5. Wisper is associated with TIA1-related protein and regulates lysyl hydroxylase 2 expression. Wisper is associated with TIA1-related protein and.
Analysis of brain and spinal cord of treated Gaa−/− mice and controls
Fig. 3. A circadian rhythm in fibroblast wound-healing response.
Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.
Fig. 3 BX795 blocks the synthesis of HSV-1 virions.
Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.
Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 6. HERV-K activation by TDP-43 and identification of binding sites on LTR. (A and B) Stem cell–derived neurons were transfected with either pcDNA.
Fig. 1. CD31 is present throughout the human renal vasculature.
Fig. 1. Aberrant JNK pathway activation in mouse models of ALS and in spinal cord tissue from patients with sporadic ALS. Aberrant JNK pathway activation.
Fig. 5. Remnants of PS+ platelets induce neutrophil macroaggregation.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.
Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.
Fig. 1. mGlu7 expression is reduced in RTT autopsy samples.
Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.
Fig. 2. Binding of recombinant full-length Lm-411 to muscle receptors, myotubes, and self-polymerization is enhanced by mag and αLNNd. Binding of recombinant.
Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.
Fig. 5 Local gel scaffold for T cell memory response.
Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.
Fig. 1 BX795 suppresses HSV-1 infection.
Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.
Fig. 1. PGBD5-expressing cells do not tolerate deficiency of nonhomologous end-joining DNA repair. PGBD5-expressing cells do not tolerate deficiency of.
Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.
Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.
Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.
Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.
Fig. 3. Morphological changes associated with glial activation were reduced in 16-month-old APP/PS1;C3 KO mice. Morphological changes associated with glial.
Fig. 7. Treatment with DLK inhibitors reduces p-c-Jun and protects against neuronal and synaptic loss in vitro and in ALS mouse models. Treatment with.
Fig. 1. Generation of forebrain progenitor cells with regional identity from human iPSCs. Generation of forebrain progenitor cells with regional identity.
Fig. 1 CSPG4 is expressed in GBM specimens and GBM-NS and associated with more aggressive disease. CSPG4 is expressed in GBM specimens and GBM-NS and associated.
Fig. 3. HECTD2 contains a naturally occurring polymorphism at A19, which mislocalizes to the cytosol. HECTD2 contains a naturally occurring polymorphism.
Bexarotene is neuroprotective in mouse and human HD neurons in vitro
Fig. 3 CSF1 is expressed in human melanoma.
Fig. 5 DMN-Tre labeling is selective for live mycobacteria.
Fig. 1. Specificity of FolamiR uptake in cancer cells in culture.
Fig. 6 DMF inhibits NF-κB translocation upon infection.
LXRα enhances glucose uptake and O‐GlcNAc signaling via activation of the hexosamine biosynthetic pathway (HBP) in cultured cardiomyocytes LXRα enhances.
Fig. 7. Scale-up of AAV vector–mediated liver gene transfer of secretable GAA to nonhuman primates. Scale-up of AAV vector–mediated liver gene transfer.
Nox1 as a potential therapeutic target to inhibit matricellular-mediated endothelial senescence. Nox1 as a potential therapeutic target to inhibit matricellular-mediated.
Effect of D‐Asp treatment on myelination and remyelination in cerebellar organotypic slices Effect of D‐Asp treatment on myelination and remyelination.
Fig. 6 Combination therapy with LVSOD2 and LVshCTGF preserves flap volume and reduces fibrosis after RT. Combination therapy with LVSOD2 and LVshCTGF preserves.
Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.
Fig. 2. BET inhibition enhances PARPi-induced DNA damage.
Adenosine-induced osteogenic differentiation of hiPSCs involves A2bR
Murine gingival MSCs and skin MSCs produce and secrete IL-1RA–EV
FGF/ERK inhibition accelerates neural fate conversion of EpiSCs.
Overexpression of cyp7a1 in the liver ameliorates tumor-induced liver inflammation. Overexpression of cyp7a1 in the liver ameliorates tumor-induced liver.
Integrin β3 is dispensable for RhoA activity and contractility.
Chd5-deficient NSCs generate excessive astrocytes at the expense of neurons. Chd5-deficient NSCs generate excessive astrocytes at the expense of neurons.
Fig. 6 Metarrestin treatment reduces pre-RNA synthesis and Pol I occupancy at rDNA without changing rDNA chromatin states. Metarrestin treatment reduces.
Aβ-mediated Ras-MAPK signaling and Cyclin D1 expression in B103 cells are dependent on APP expression and can be reversed with MEK or Ras inhibition. Aβ-mediated.
Ubiquitin mediates the interaction between Smo and Vps36.
S-Affs colocalize with SUMO in mammalian cells.
Activity regulates eEF2K-dependent spine morphogenesis.
Fig. 4 Cdc42 enhances the cellular uptake of EVs.
Fig. 5. miR p inhibits the translational initiation of CACNA1A IRES–driven α1ACT by eIF4AII and eIF4GII. miR p inhibits the translational initiation.
Higher-ordered oligomeric α-synuclein induces complex morphofunctional activation of microglia. Higher-ordered oligomeric α-synuclein induces complex morphofunctional.
Fig. 5 C9orf72 knockdown disrupts autophagy induction.
Volume 15, Issue 5, Pages (May 2007)
Fig. 4 Rotavirus induces the type I IFN pathway and release of ATP by tumor cells. Rotavirus induces the type I IFN pathway and release of ATP by tumor.
Presentation transcript:

Fig. 1. β-APP overexpression or exposure to inflammatory mediators induces sIBM-like pathology in cultured rat myocytes that is abrogated by arimoclomol. β-APP overexpression or exposure to inflammatory mediators induces sIBM-like pathology in cultured rat myocytes that is abrogated by arimoclomol. (A and B) Cytoplasmic inclusion bodies (white arrows) in rat myocytes transfected with full-length human β-APP that are immunoreactive for β-APP and ubiquitin, and TDP-43 and ubiquitin. (C) The number of rat myocytes containing ubiquitinated inclusion bodies as a percentage of the total number of myocytes present [n = 3; *P < 0.05, one-way analysis of variance (ANOVA)]. Ari, arimoclomol. (D and E) Expression of TDP-43 (green) after empty vector (EV) or β-APP transfection and arimoclomol treatment and the number of rat myocytes with cytoplasmic mislocalization of TDP-43 (n = 3; *P < 0.001, unpaired t test). (F and G) TDP-43 expression (green) after exposure to inflammatory mediators and arimoclomol and quantification of TDP-43 mislocalization in cytokine-treated cultures (n = 3; *P < 0.05, unpaired t test). (H) Western blot analysis of TDP-43 expression in rat myocyte cultures exposed to cytokines in the presence and absence of arimoclomol. (I and J) Images show the expression of NF-κB subunit p65 (green) in β-APP–transfected cultures [4′,6-diamidino-2-phenylindole (DAPI)–labeled nuclei in blue] and cultures exposed to cytokines in the presence and absence of arimoclomol. (K) The number of rat myocytes with the nuclear subunit of NF-κB, p65 as a percentage of the total number of myocytes present (n = 3; *P < 0.05, one-way ANOVA). Error bars represent SEM. Scale bars, 10 μm (A and B); 20 μm (D, F, I, and J). Mhoriam Ahmed et al., Sci Transl Med 2016;8:331ra41 Published by AAAS